

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our directors and/or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.



CStone Pharmaceuticals

基石藥業

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2616)

VOLUNTARY ANNOUNCEMENT

THE COMPANY INCLUDED IN SOUTHBOUND STOCK CONNECT

This announcement is made by CStone Pharmaceuticals (the “Company,” together with its subsidiaries, collectively referred to as the “Group” or “CStone”) on a voluntary basis for the purpose of keeping the shareholders of the Company and potential investors abreast of the latest business development of the Group.

.....

CStone today announced that the shares of the Company issued and listed on the Stock Exchange of Hong Kong Limited have been included in the eligible securities list for southbound trading under Stock Connect, with effect from September 7, 2026.

Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, commented, “Inclusion in the Southbound Stock Connect reflects strong recognition by the capital markets of our innovation capabilities and long-term growth potential. We expect this inclusion to further broaden our investor base and enhance the liquidity of our shares in the secondary market. Looking ahead, we will continue to advance the global development of our core assets, strengthen our competitive position through efficient pipeline execution and commercialization, and deliver sustainable, long-term value for our shareholders.”

CStone remains committed to addressing unmet clinical needs worldwide through a differentiated innovation strategy. Our core asset, CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, continues to progress efficiently through global Phase I/II clinical development, with the first wave of global Phase III registrational trials expected to be initiated by the end of 2026. Our proprietary EGFR/HER3 bispecific ADC, CS5007, has also entered global Phase I clinical development, with the study being conducted concurrently in China and Australia. In addition, multiple next-generation ADC programs, along with bispecific antibody programs in immunology and inflammation, are advancing toward Investigational New Drug (IND) submissions.

Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

About CStone

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas. Dedicated to addressing patients' unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched four innovative drugs and secured approvals for 21 new drug applications covering nine indications. The Company's pipeline comprises 13 promising innovative candidates, including antibody-drug conjugates (ADCs), mono- and multispecific antibodies, immunotherapies and precision medicines. CStone has an experienced management team with comprehensive capabilities spanning the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization.

For more information about CStone, please visit: www.cstonepharma.com.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the securities of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By Order of the Board
CStone Pharmaceuticals
Dr. Wei Li
Chairman

Suzhou, the People's Republic of China, September 7, 2026

As at the date of this announcement, the Board comprises Dr. Wei Li as Chairman and non-executive director, Dr. Jianxin Yang as executive director, Mr. Kenneth Walton Hitchner III and Mr. Edward Hu as non-executive directors, and Mr. Kenneth Howard Jarrett, Ms. Fang Xie and Ms. Catherine Yen as independent non-executive directors.